The DEA is congressionally mandated to
prepare high priority strategic drug intelligence in order to
provide lawmakers with the most current information on
availability, demand, production, cultivation, transportation, and
distribution, as well as the effects of drugs on the abusers and
society.
5. DEA intends to use NDTS
response data for several purposes. DEA analysts will use NDTS data
to corroborate drug intelligence data obtained from other sources
that include: federal drug investigations initiated and conducted
through the Organized Crime Drug Enforcement (OCDETF) Task Forces
program administered by the Department of Justice; federal drug
seizure data collected through the National Seizure System
maintained by the DEA El Paso Intelligence Center (EPIC); national
level drug demand and usage studies conducted by the Department of
Health and Human Services that include the National Survey on Drug
Use and Health (NSDUH), the Monitoring the Future (MTF) study, the
Centers for Disease Control (CDC) reports on drug overdose deaths,
and the Treatment Episode Data Set (TEDS) for admissions to drug
treatment agencies; and reports and summaries from intelligence
reporting from other federal state and local law enforcement
agencies, drug task forces, and investigators’ associations.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.